Lakefront Biotherapeutics NV 2022 AR2
The report highlights Galapagos' major strategic transformation in 2022, shifting to a patient-focused R&D model in immunology and oncology. The company expanded its capabilities through the acquisitions of CellPoint and AboundBio, gaining access to a decentralized point-of-care CAR-T manufacturing platform. Financially, Galapagos reported Jyseleca net sales of ’87.6 million in Europe and ended the year with a strong balance sheet of ’4.1 billion in cash and current financial investments. On the sustainability front, the company completed a new materiality assessment to focus its ambitions on patients, people, planet, and trust, while setting a target to become carbon neutral by 2028.
Company: Lakefront Biotherapeutics NV
Sector: Professional & technical services
Country: Belgium
Year: 2022
Type: AR2
Pages: 274
Back to company
Lakefront Biotherapeutics NV
Annual Report
The report highlights Galapagos' major strategic transformation in 2022, shifting to a patient-focused R&D model in immunology and oncology. The company expanded its capabilities through the acquisitions of CellPoint and AboundBio, gaining access to a decentralized point-of-care CAR-T manufacturing platform. Financially, Galapagos reported Jyseleca net sales of ’87.6 million in Europe and ended the year with a strong balance sheet of ’4.1 billion in cash and current financial investments. On the sustainability front, the company completed a new materiality assessment to focus its ambitions on patients, people, planet, and trust, while setting a target to become carbon neutral by 2028.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees